期刊文献+

我国前列腺癌的健康筛查和早期诊疗方面的回顾和总结 被引量:23

Review and summary of health screening and early diagnosis and treatment of prostate cancer in China
原文传递
导出
摘要 前列腺癌是世界范围内高发和主要的致死癌症之一。我国前列腺癌的发病率虽然低于欧美国家,但呈现出逐年明显增长的趋势。同时,既往我国的前列腺癌患者确诊时晚期比例高,严重影响了治疗效果。近年来,在我国广大医务人员的共同努力下,我国在前列腺癌的早期筛查、早期诊断和治疗方面都取得了巨大的进步。本文就近年来我国在前列腺癌健康筛查和早期治疗方面的进展进行了回顾和总结,以为临床早期诊治前列腺癌提供依据。 Prostate cancer is one of the most common and fatal cancers worldwide.Although the incidence of prostate cancer in China is lower than that of European and American countries,it shows a trend of significant increase year by year.At the same time,the high proportion of advanced prostate cancer patients in China at the time of diagnosis has seriously affected the treatment effect.In recent years,with the joint efforts of the majority of Chinese medical staff,there has made great progress in the early screening,early diagnosis and treatment of prostate cancer.This article reviews and summarizes the progress in health screening and early treatment of prostate cancer in China in recent years to provide a basis for early clinical diagnosis and treatment of prostate cancer.
作者 王栋 李沛衡 纪志刚 谢燚 Wang Dong;Li Peiheng;Ji Zhigang;Xie Yi(Department of Urology,Chinese Academy of Medical Sciences,Peking Union Medical College,Peking Union Medical College Hospital,Beijing 100730,China)
机构地区 中国医学科学院
出处 《国际外科学杂志》 2020年第9期577-581,共5页 International Journal of Surgery
关键词 前列腺肿瘤 筛查 早期诊断 治疗应用 Prostatic neoplasms Screening Early diagnosis Therapeutic uses
  • 相关文献

参考文献9

二级参考文献39

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 4Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 5Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 6Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 7Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 8Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 9Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.
  • 10Darer A,Soret JY, Coblentz Y, et al. The usefulness of prostate- specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol, suppl, 1988, 11 :S53-S57.

共引文献4391

同被引文献223

引证文献23

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部